Is Compounded Semaglutide Being Banned? What the New FDA 503B Rules Mean for You
US guide to FDA 503B outsourcing facility rules affecting compounded semaglutide — who is impacted, timeline, and what to discuss with your prescriber.
If you have been using compounded semaglutide — often marketed as a lower-cost alternative to Wegovy — you may have seen headlines about FDA crackdowns on 503B outsourcing facilities. Here is what the new rules mean for US patients in plain language.
Background: why compounded semaglutide existed
Branded Wegovy and Ozempic (semaglutide) saw massive demand with limited supply. 503B outsourcing pharmacies began producing compounded versions using semaglutide API, often at lower cash prices ($200–$400/month vs $1,300+ list for Wegovy).
The FDA has consistently stated that semaglutide is not on the shortage list that permits widespread compounding — and has issued warning letters to facilities producing copies of the branded drug.
What changed with 503B enforcement
The FDA's updated scrutiny of 503B outsourcing facilities affects:
- Bulk compounding of semaglutide for national distribution
- Pharmacies without valid patient-specific prescriptions
- Facilities using non-FDA-approved API sources
- Marketing of "generic Wegovy" — semaglutide has no FDA-approved generic
Some compounding pharmacies have voluntarily stopped semaglutide production. Others operate under state board oversight with narrower patient-specific compounding.
Who is most affected
| Patient profile | Likely impact | |----------------|---------------| | Cash-pay compounded semaglutide user | High — supply may end abruptly | | Wegovy with insurance PA approved | Low — branded supply unaffected | | Telehealth compound prescriptions | High — many platforms pausing | | Ozempic for off-label weight loss | Moderate — separate supply chain |
What to do now
- Contact your compounding pharmacy — ask directly about continuity of supply
- Talk to your prescriber about transitioning to branded Wegovy or Zepbound
- Start a prior authorization appeal if insurance previously denied coverage — use our free PA appeal generator
- Check manufacturer patient assistance — Novo Nordisk and Eli Lilly offer programs for qualifying patients
- Do not stockpile without medical guidance — dosing and storage requirements differ
Cost context (USD)
- Wegovy list price: ~$1,300–$1,500/month
- Zepbound list price: ~$1,000–$1,200/month
- Compounded semaglutide (where available): ~$200–$400/month
- With insurance PA approval: copays often $25–$150/month
Track the transition
If you switch from compounded to branded medication, log the change date, new dose, and any side effect shifts. GLPPal helps you maintain one continuous timeline — download on the App Store.
